MA27720A1 - Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP - Google Patents

Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP

Info

Publication number
MA27720A1
MA27720A1 MA28498A MA28498A MA27720A1 MA 27720 A1 MA27720 A1 MA 27720A1 MA 28498 A MA28498 A MA 28498A MA 28498 A MA28498 A MA 28498A MA 27720 A1 MA27720 A1 MA 27720A1
Authority
MA
Morocco
Prior art keywords
disorder
sexual
dysfunction
male
female
Prior art date
Application number
MA28498A
Other languages
English (en)
Inventor
David Hepworth
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305916A external-priority patent/GB0305916D0/en
Priority claimed from GB0329143A external-priority patent/GB0329143D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27720A1 publication Critical patent/MA27720A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)

Abstract

l'hypercalciurie, un ictus, le glaucome, l'obésité, des maladies métaboliques, le syndrome métabolique, le diabète, la tolérance entravée au glucose, la rétinopathie diabétique, la neuropathie diabétique, des troubles menstruels, l'accouchement avant terme, la pré-éclampsie, l'endométriose et des troubles de la reproduction, la stérilité masculine et la stérilité féminine, le syndrome d'ovaire polykystique, un défaut d'implantation, l'asthme, l'inflammation, la leucémie, la douleur, la douleur provoquée par un cancer, la dépression, la pharmacodépendance, la cirrhose, l'épilepsie, des troubles affectifs, la démence et la confusion gériatrique, des troubles gastro-intestinaux, la diarrhée, le syndrome du côlon irritable, la cicatrisation de plaies, les ulcères diabétiques et les ulcères veineux et les escarres de décubitus, le choc septique, la sécrétion d'acide gastrique, l'hyperréninémie, la fibrose kystique, une resténose, l'athérosclérose, un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel, un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD), un dysfonctionnement de l'érection masculine (MED), un trouble de désir sexuel hypoactif, un trouble orgasmique et un trouble douloureux sexuel. 13. Composé, méthode ou utilisation suivant la revendication 12, dans lequel le trouble ou l'affection est choisi entre un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel, un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD), un dysfonctionnement de l'érection masculine (MED), un trouble de désir sexuel hypoactif, un trouble orgasmique et un trouble douloureux sexuel. 14. Composé, méthode ou utilisation suivant la revendication 13, dans lequel le trouble ou l'affection est choisi entre un dysfonctionnement sexuel féminin (FSD), un trouble d'éveil sexuel féminin (FSAD), un dysfonctionnement sexuel masculin (MSD) et un dysfonctionnement, de l'érection masculine (MED).
MA28498A 2003-03-14 2005-09-14 Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP MA27720A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305916A GB0305916D0 (en) 2003-03-14 2003-03-14 New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en) 2003-12-16 2003-12-16 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
MA27720A1 true MA27720A1 (fr) 2006-01-02

Family

ID=32992599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28498A MA27720A1 (fr) 2003-03-14 2005-09-14 Dérivés d'acide 3-(1-[3-(1,3-benzothiazole-6-yl)propylcarbamoyl]cycloalkyl)propano??que servant d'inhibiteurs de NEP

Country Status (25)

Country Link
US (1) US20040180941A1 (fr)
EP (1) EP1606272A1 (fr)
JP (1) JP3923512B2 (fr)
KR (1) KR20050110003A (fr)
AP (1) AP2005003393A0 (fr)
AR (1) AR043551A1 (fr)
AU (1) AU2004220269A1 (fr)
BR (1) BRPI0408377A (fr)
CA (1) CA2519072A1 (fr)
CL (1) CL2004000512A1 (fr)
EA (1) EA200501204A1 (fr)
EC (1) ECSP056017A (fr)
HR (1) HRP20050797A2 (fr)
IS (1) IS8003A (fr)
MA (1) MA27720A1 (fr)
MX (1) MXPA05009788A (fr)
NL (1) NL1025709C2 (fr)
NO (1) NO20054169L (fr)
OA (1) OA13039A (fr)
PA (1) PA8597401A1 (fr)
PE (1) PE20050310A1 (fr)
TN (1) TNSN05227A1 (fr)
TW (1) TW200504038A (fr)
UY (1) UY28226A1 (fr)
WO (1) WO2004080985A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024241A1 (en) * 2004-08-02 2006-02-02 Bebaas, Inc. Vitamin B12 compositions
WO2006027680A1 (fr) * 2004-09-10 2006-03-16 Pfizer Limited Derives d'acide 3-(1-carbamoylcyclohexyl)propionique comme inhibiteurs de l'enzyme endopeptidase neutre
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
CA2616366A1 (fr) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Nouveaux composes pharmaceutiques
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
EP2051696A2 (fr) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Compositions liquides stables de lévétiracétam et procédés
KR101177866B1 (ko) 2011-03-24 2012-08-28 주식회사 케이엠더블유 케이블 접속 장치
JP2021527875A (ja) * 2018-06-14 2021-10-14 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ Ｃｇｍｐ特異的ホスホジエステラーゼ５阻害剤の薬学的組成物により勃起不全を治療するための方法
CN112997258A (zh) * 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 用cGMP特异性磷酸二酯酶5抑制剂药物组合物治疗勃起功能障碍的方法
WO2020064173A1 (fr) 2018-09-25 2020-04-02 Antabio Sas Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
WO2021091908A1 (fr) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Compositions contenant du cannabidiol (cbd) à action périphérique et leurs utilisations pour améliorer la fonction sexuelle féminine ou traiter des troubles sexuels féminins
GB202402524D0 (en) * 2024-02-22 2024-04-10 Futura Medical Developments Ltd Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
NL175059C (nl) * 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) * 1985-08-05 1987-02-05 Hoechst Ag Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
CA2189355A1 (fr) * 1995-03-01 1996-09-06 Yasuo Onoda Derives d'imidazoquinazoline
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EE200300469A (et) * 2001-03-28 2004-02-16 Pfizer Inc. N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul

Also Published As

Publication number Publication date
CA2519072A1 (fr) 2004-09-23
NL1025709C2 (nl) 2005-03-14
CL2004000512A1 (es) 2005-01-21
MXPA05009788A (es) 2005-10-26
AP2005003393A0 (en) 2005-09-30
BRPI0408377A (pt) 2006-03-21
EA200501204A1 (ru) 2006-06-30
AR043551A1 (es) 2005-08-03
WO2004080985A1 (fr) 2004-09-23
AU2004220269A1 (en) 2004-09-23
PA8597401A1 (es) 2005-05-24
JP2006526572A (ja) 2006-11-24
IS8003A (is) 2005-08-29
OA13039A (en) 2006-11-10
NO20054169L (no) 2005-12-07
UY28226A1 (es) 2004-11-08
NO20054169D0 (no) 2005-09-07
US20040180941A1 (en) 2004-09-16
JP3923512B2 (ja) 2007-06-06
KR20050110003A (ko) 2005-11-22
NL1025709A1 (nl) 2004-09-16
TW200504038A (en) 2005-02-01
ECSP056017A (es) 2006-01-27
EP1606272A1 (fr) 2005-12-21
PE20050310A1 (es) 2005-05-04
HRP20050797A2 (en) 2006-02-28
TNSN05227A1 (fr) 2007-06-11

Similar Documents

Publication Publication Date Title
NO152446B (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 9-substituerte hypoxantinderivater
NO168795B (no) Fiberoptisk undervannsledning for telekommunikasjonsformaal
TNSN95051A1 (fr) Procede de production d'une forme pharmaceutique d'azithromycine
CN1168376A (zh) 制备喜勃酮的方法
BRPI0519106A2 (pt) compostos, uso destes, processo para sua fabricaÇço, composiÇÕes farmacÊuticas, mÉtodo para o tratamento e/ou profilaxia de doenÇas que sço associadas com a dpp-iv
CN1111245A (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
Smith et al. Prostaglandin isosteres. 1.(8-Aza-, 8, 10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives
AR043551A1 (es) Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbomoil]cicloalquil) propanoico como inhibidores de nep, composicion farmaceutica que lo comprende y usos
NO153001B (no) Drivanordning for skip
IL90552A (en) History of 3-oxo-propanitrile compressed pyrizole, their preparation and pharmaceutical preparations containing them
FR2603888A1 (fr) Esters d'amino acides du trimethyl cyclohexanol, procede de preparation et utilisation comme medicaments
CN100338069C (zh) 制备奥氮平及其中间体的方法
US4036964A (en) Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
CA2394027A1 (fr) Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWD237426S (zh) 具點滴吊架之助行器
US2680767A (en) Pantothenylaminoethyl sulfur compounds and method for obtaining the same
DE69814420T2 (de) Stereoselektive verfahren zur herstellung von gabapentinanalogen
US4420475A (en) Silicon-bearing amides
JPH0762018B2 (ja) ジヒドロピリジンラクト−ル類
US6369218B1 (en) Isomerisation of 6β-fluorosteroids into the corresponding 6α-fluoro derivatives
US20050267096A1 (en) New indazole and indolone derivatives and their use pharmaceuticals
US4625028A (en) 6-aryluracils and selected novel intermediates used in the preparation thereof
US3923796A (en) Certain 6,7-dioxo-2H-pyrrolo-{8 2,1-b{9 thiazines
US3209026A (en) Cyclohexyloxycyclopropylamines
NO178622B (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive kynurensyrederivater, samt mellomprodukter egnet for fremstilling derav